Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL30349640

NC(=O)c1ccc(N2CCNCC2)nc1.O=C(O)C(F)(F)F

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.52
KCNH2 Q12809 2/20 0.48
HDAC2 Q92769 4/20 0.47
HDAC3 O15379 3/20 0.47
OPRM1 P35372 1/20 0.47
OPRK1 P41145 1/20 0.47
PARP1 P09874 1/20 0.47
HRH4 Q9H3N8 1/20 0.47
HDAC1 Q13547 2/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
SMO Q99835 1/20 0.46
UBE2T Q9NPD8 1/20 0.45
HRH3 Q9Y5N1 1/20 0.44
KDM1A O60341 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2706925 0.91 PARP1 (0.53) HPGDSKCNH2HDAC2HDAC3OPRM1
SCHEMBL29524173 0.91 PARP1 (0.53) HPGDSKCNH2HDAC2HDAC3OPRM1
Hydrochloric Acid SCHEMBL29475075 0.89 PARP1 (0.52) HPGDSKCNH2HDAC2HDAC3OPRM1
Trifluoroacetic Acid SCHEMBL6824156 0.84 ALDH1A1 (0.59) HPGDSKCNH2HDAC2HDAC3HRH4
Trifluoroacetic Acid SCHEMBL30349693 0.84 OPRM1 (0.48) HPGDSOPRM1OPRK1PARP1SMO
SCHEMBL1896186 0.81 KCNH2 (0.53) HPGDSKCNH2HDAC2HDAC3HDAC1
Trifluoroacetic Acid SCHEMBL6392063 0.80 ALDH1A1 (0.57) PARP1
Hydrochloric Acid SCHEMBL31552815 0.79 KCNH2 (0.52) HPGDSKCNH2HDAC2HDAC3HDAC1
SCHEMBL7547417 0.79 KCNH2 (0.52) HPGDSKCNH2HDAC2HDAC3HDAC1
SCHEMBL7550033 0.79 KCNH2 (0.52) HPGDSKCNH2HDAC2HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230091225-A1 Bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof HINOVA PHARMACEUTICALS INC. (CN) 2023-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230091225-A1 Bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof AR, ADRM1, PSMA1 HPGDS 3172/4885KCNH2 4759/4885HDAC2 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.